Celgene's (NASDAQ:CELG) Vidaza, which began facing U.S. generic competition in September of 2013, just can't seem to catch a break.
First there was the generic competition -- which dropped sales by 27% year-over-year last quarter to $148 million. And more recently the drug failed a phase 3 trial in elderly patients with newly-diagnosed acute myeloid leukemia. The drug failed to provide a statistically significant benefit to median overall survival.
So, should this drug's failure dramatically affect the Celgene investing thesis?
In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson answer.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.